Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: Successful treatment with recombinant interferon-gamma

被引:53
作者
Yagi, H [1 ]
Tokura, Y [1 ]
Furukawa, F [1 ]
Takigawa, M [1 ]
机构
[1] HAMAMATSU UNIV SCH MED, DEPT DERMATOL, HAMAMATSU, SHIZUOKA 43131, JAPAN
关键词
Ki-1(+) lymphoma; lymphomatoid papulosis; cutaneous T-cell lymphoma; anaplastic large cell lymphoma;
D O I
10.1111/1523-1747.ep12330845
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Primary cutaneous CD30 (Ki-1)(+) large cell lymphoma (Kit) and lymphomatoid papulosis (LyP) type A are collectively termed as primary cutaneous CD30-positive lymphoproliferative disorders. We examined the cytokine profile of skin-infiltrating cells and the therapeutic efficacy of recombinant interferon-gamma (rIFN-gamma) in primary cutaneous Kit and LyP type A. By reverse transcriptase-polymerase chain reaction, mRNAs for interleukin-4 (IL-4) and IL-10 were detected in the dermis of skin lesions in all cases (three cases of KiL and four cases of LyP). In addition, tissue from one Kit patient transcribed IL-2 and IFN-gamma messages, and one LyP patient showed IL-2 mRNA. In contrast, normal skin from ten healthy donors contained mRNA for IL-2 or IFN-gamma, or both, but not for IL-4. Before the therapeutic trial of rIFN-gamma, the response of skin lesions was assessed by a predictive skin test with local injection of rIFN-gamma (0.5 x 10(6) Japan Reference Units [JRU; 1 JRU roughly corresponds to 4 NIH units]) for 3 consecutive days in two KiL and two LyP patients, Numbers of skin-infiltrating CD30(+) cells were decreased, and transcription of mRNA for IL-4 and IL-10 was downregulated after the skin test in one Kit and two LyP cases. One Kit patient showed no histologic response or change in mRNA expression. In the therapeutic trial, rIFN-gamma (total doses of 1.2-4.0 x 10(7) JRU) was administered intravenously (n = 2) or locally (n = 2). In three patients who responded to the skin test, the lesions were objectively improved and the numbers of skin-infiltrating CD30(+) cells were markedly decreased after the therapeutic trial, No improvement was observed in one Kit patient who did not respond to the skin test, These findings suggest that the skin-infiltrating CD30(+) cells in Kit and LyP have a Th2 cytokine profile and raise the possibility that the administration of rIFN-gamma improves the conditions by inhibiting cytokine mRNA transcription and proliferation of CD30(+) cells.
引用
收藏
页码:827 / 832
页数:6
相关论文
共 47 条
[1]   12 CASES OF KI-1 POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OF SKIN [J].
BANERJEE, SS ;
HEALD, J ;
HARRIS, M .
JOURNAL OF CLINICAL PATHOLOGY, 1991, 44 (02) :119-125
[2]  
BELJAARDS RC, 1989, AM J PATHOL, V135, P1169
[3]  
BELJAARDS RC, 1992, BRIT J DERMATOL, V126, P596
[4]  
BELJAARDS RC, 1993, CANCER, V71, P2097, DOI 10.1002/1097-0142(19930315)71:6<2097::AID-CNCR2820710626>3.0.CO
[5]  
2-7
[6]   RECOMBINANT GAMMA INTERFERON IN TREATMENT OF PATIENTS WITH ATOPIC-DERMATITIS AND ELEVATED IGE LEVELS [J].
BOGUNIEWICZ, M ;
JAFFE, HS ;
IZU, A ;
SULLIVAN, MJ ;
YORK, D ;
GEHA, RS ;
LEUNG, DYM .
AMERICAN JOURNAL OF MEDICINE, 1990, 88 (04) :365-370
[7]  
BORISH L, 1993, J ALLERGY CLIN IMMUN, V92, P123, DOI 10.1016/0091-6749(93)90046-I
[8]   THE SKIN IMMUNE-SYSTEM (SIS) - DISTRIBUTION AND IMMUNOPHENOTYPE OF LYMPHOCYTE SUBPOPULATIONS IN NORMAL HUMAN-SKIN [J].
BOS, JD ;
ZONNEVELD, I ;
DAS, PK ;
KRIEG, SR ;
VANDERLOOS, CM ;
KAPSENBERG, ML .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1987, 88 (05) :569-573
[9]   INTERFERON-ALPHA INCREASES THE FREQUENCY OF INTERFERON-GAMMA-PRODUCING HUMAN CD4+ T-CELLS [J].
BRINKMANN, V ;
GEIGER, T ;
ALKAN, S ;
HEUSSER, CH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (05) :1655-1663
[10]   ANAPLASTIC LARGE CELL KI-1 LYMPHOMA - DELINEATION OF 2 MORPHOLOGICAL TYPES [J].
CHAN, JKC ;
NG, CS ;
HUI, PK ;
LEUNG, TW ;
LO, ESF ;
LAU, WH ;
MCGUIRE, LJ .
HISTOPATHOLOGY, 1989, 15 (01) :11-34